Hivis (Diosmin)

Hivis is indicated for conditions related to impaired venous return and capillary fragility.

• Chronic venous insufficiency (CVI) presenting with leg heaviness, swelling, or varicose veins.
• Hemorrhoidal disease, including symptomatic internal or external hemorrhoids.
• Post‑thrombotic syndrome where venous circulation remains compromised after deep‑vein thrombosis.
• Venous stasis dermatitis characterized by skin changes due to poor venous drainage.
• Mild peripheral edema associated with venous disorders.

• Diosmin exerts its phlebotonic effect by enhancing venous tone and reducing capillary permeability. The flavonoid is metabolized to its active aglycone, which inhibits prostaglandin synthesis and modulates nitric oxide pathways, leading to increased smooth‑muscle contraction in venous walls. This action improves venous return, decreases venous stasis, and stabilizes the endothelial lining, thereby limiting fluid extravasation and edema formation in the affected tissues.

Adverse reactions reported with diosmin-containing products are generally mild, but rare serious events have been described.

Common

• Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia.
• Headache or mild dizziness.
• Skin flushing or mild pruritus.
• Transient increase in urinary frequency.

Serious

• Allergic reactions including rash, urticaria, or angioedema.
• Hepatic enzyme elevation or liver dysfunction.

When considering Hivis, clinicians should evaluate patient-specific factors and potential contraindications.

• Use with caution in patients with known hypersensitivity to diosmin or related flavonoids.
• Assess liver function before initiating therapy, especially in individuals with pre‑existing hepatic disease.
• Monitor for bleeding tendencies if combined with anticoagulants or antiplatelet agents.
• Avoid use during pregnancy or lactation unless the benefit outweighs potential risk, as safety data are limited.
• Consider renal impairment; dose adjustment may be required in severe cases.
• Review concomitant use of other venotonic or phytotherapeutic products to prevent additive effects.

Diosmin may interact with certain medications, influencing efficacy or safety.

Avoid

• Concurrent use with potent anticoagulants (e.g., warfarin, direct oral anticoagulants) due to increased bleeding risk.
• Combination with high‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that also affect platelet function.

Use with caution

• Co‑administration with other phlebotonic agents or herbal extracts (e.g., hesperidin, rutin) may potentiate venous effects.
• Use alongside diuretics, as fluid balance changes could modify therapeutic response.
• Patients on antihypertensive drugs should be monitored for additive blood‑pressure lowering effects.